Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
Oculis Announces Successful End-of-Phase 2 Meeting With the FDA July 27, 2020
Oculis S.A. recently announced it has successfully completed an End-of-Phase 2 meeting with the US FDA for OCS-01 in two...Croda Strengthens Position in Life Sciences With Acquisition of Avanti Polar Lipids July 9, 2020
Croda International Plc recently announced it has agreed to acquire Avanti Polar Lipids, Inc., a knowledge-intensive leader in lipid-based drug delivery technologies for next-generation pharmaceuticals…..
NOVA Thin Film Pharmaceuticals & Quality Chemical Laboratories Announce Partnership in Formation & Commencement of Soluble Thin Film Operations June 2, 2020
NOVA Thin Film Pharmaceuticals LLC (NTFP) recently announced its formation and the commencement of its soluble thin film operations……
CanSino Biologics & Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine May 20, 2020
CanSino Biologics Inc. and Precision NanoSystems (PNI) recently announced a co-development agreement of a mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19. The parties will…
Singota Solutions Collaborates With Noveome Biotherapeutics to Manufacture Promising Therapy to Treat Severe Condition in People Infected with COVID-19 May 13, 2020
Singota Solutions has been selected to collaborate with Noveome Biotherapeutics, Inc. to manufacture the ST266 investigational drug product, a biologic being evaluated in….
Adare Pharmaceuticals Acquires Orbis Biosciences May 5, 2020
Adare Pharmaceuticals, Inc. recently announced it has acquired the pharmaceutical technology company, Orbis Biosciences, Inc. The acquisition of Orbis will….
SPECIAL FEATURE - Prefilled Syringes & Parenteral Manufacturing: Innovations, Challenges & Solutions May 5, 2020
Contributor Cindy H. Dubin features several leading companies’ innovations in delivery devices as well as how contract parenteral manufacturers are addressing the ever-demanding challenges, issues, and opportunities related to delivering biologics and small molecules.
ANALYTICAL SERVICES - Applying Innovative Thinking & Techniques to Reduce Time-to-Market May 4, 2020
Ramesh Jagadeesan, PhD, says that while CDMOs have the capacity to support pharmaceutical companies with their analytical requirements for both small and large-scale projects, the opportunity exists to increase speed to market with innovative thinking.
Quotient Sciences & CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm April 30, 2020
A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was recently announced today...TFF Pharmaceuticals Announces R&D Collaboration for a Universal Influenza Vaccine April 15, 2020
TFF Pharmaceuticals, Inc. recently announced that it has entered into a research collaboration with the University of Georgia’s Center for Vaccines and Immunology (CVI), along with….
SPECIAL FEATURE - Excipients: Matching Ingredients to Molecules Improves Functionality April 1, 2020
Contributor Cindy Dubin speaks with several leading excipient manufacturers on how their excipient offerings are improving drug release, solubility, taste, physical characteristics, viscosity, and more for a range of molecules.
ORAL THIN FILMS - Misconceptions, Advantages & Limitations About an Emerging Drug Delivery System March 31, 2020
Srinivasan Shanmugam, PhD, says due to advancements in the science behind OTF design, as well as the predicted increase in OTF market valuation, this drug delivery system is becoming increasingly popular.
SPECIAL FEATURE - Improving Bioavailability & Solubility: Understand Your Molecule March 3, 2020
Contributor Cindy H. Dubin asked several leading companies about how they are currently overcoming today’s most pressing bioavailability and solubility challenges for their pharma clients.
INTRATUMORAL DELIVERY - Combining Local & Systemic Treatments: Could Immuno-Oncology Finally Enable Local Intratumoral Delivery? March 2, 2020
Lewis H. Bender, MA, MBA, says cancer is a local and systemic disease, and new forms of local treatment, such as intratumoral dosing coupled with systemic immunotherapy, are being explored.
Oculis Announces Positive OCS-01 Phase 2 Data February 14, 2020
Oculis S.A. recently reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone,...Adare Pharmaceuticals & NLS Pharmaceutics Collaborate to Develop Controlled-Release Candidates January 15, 2020
Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. recently announced a collaboration to develop mazindol (MZD) CR product candidates for the treatment of….
Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals December 4, 2019
Appili Therapeutics Inc. recently announced it has entered into a commercialization agreement with Saptalis Pharmaceuticals LLC on ATI-1501, Appili’s liquid suspension reformulation of the…..
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial December 4, 2019
Soligenix, Inc. recently announced it has completed patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study...CDMO SELECTION - Ready to Launch: Developing Your Biologic With an Eye Toward Commercial Supply November 26, 2019
Stacey Treichler, PhD, believes the development process for new biologics is complex and requires a substantial amount of time and resources, and reviews some of the areas where careful choice of CDMO is key, including cell line development and cGMP manufacturing capabilities, and how an integrated approach can be beneficial.